Amyloidosis News - October 2021

Utility of Functional Assessments in the Prognosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas TX, explain the usefulness of the six-minute walk test in clinical practice and to patients. Read More ›

Addressing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Through Preservation of Transthyretin
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, review the rationale for stabilization as the optimal approach to addressing transthyretin amyloid cardiomyopathy. Read More ›

Improving nurses’ knowledge of specific cardiovascular symptoms may enhance clinical suspicion resulting in early diagnosis of hereditary transthyretin amyloidosis and prompt intervention. Read More ›

Endomyocardial biopsy is recommended for TTR cardiac amyloidosis diagnosis in elderly patients, based on false-positive bone scintigraphy case. Read More ›

Adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression in patients with newly diagnosed AL. Read More ›

Myocardial involvement was more common and distinct in male patients with variant transthyretin amyloidosis. Read More ›

Since newly approved treatments can specifically inhibit further deposition of amyloid material, early diagnosis of cardiac involvement in transthyretin amyloidosis (ATTR) before appearance of left ventricular hypertrophy is advisable. Read More ›

Early diagnosis of ATTRv may facilitate early treatment initiation with disease-modifying therapy. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: